121,95 €
121,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
61 °P sammeln
121,95 €
121,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
61 °P sammeln
Als Download kaufen
121,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
61 °P sammeln
Jetzt verschenken
121,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
61 °P sammeln
  • Format: PDF

This book provides a comprehensive review of diagnosis and treatments of renal cell carcinoma (RCC) for practitioners and researchers with an interest in this disease. A major aim of the book is to present the most important and most recent advances in molecular bases and targeted therapy for this neoplasm. The remarkable resistance to chemotherapy and radiotherapy and the minimum contribution of cancer genes that commonly mutate in other adult epithelial cancers have made RCC highly distinct from other types of solid neoplasms. In the past decade, however, treatment options for RCC have been…mehr

  • Geräte: PC
  • ohne Kopierschutz
  • eBook Hilfe
  • Größe: 11.59MB
Produktbeschreibung
This book provides a comprehensive review of diagnosis and treatments of renal cell carcinoma (RCC) for practitioners and researchers with an interest in this disease. A major aim of the book is to present the most important and most recent advances in molecular bases and targeted therapy for this neoplasm. The remarkable resistance to chemotherapy and radiotherapy and the minimum contribution of cancer genes that commonly mutate in other adult epithelial cancers have made RCC highly distinct from other types of solid neoplasms. In the past decade, however, treatment options for RCC have been expanding and moving quickly toward laboratory-based and molecular-targeted therapies. Advances in RCC therapy also have brought novel treatment options to other types of cancer, such as a TKI for hepatocellular carcinoma and gastrointestinal tumors, as well as mTOR inhibitors to progressive neuroendocrine tumors of pancreatic origin and to breast cancer, suggesting that RCC is no longer an "orphan disease" in the field of molecular oncology. Additional topics covered in the book include pharmacokinetics and pharmacodynamics in molecular-targeted agents and the putative mechanism of resistance to anti-angiogenic agents, such as intratumoral heterogeneity or cancer stem cell population. This volume provides the latest and most useful information for all readers who are eagerly devoted to curing renal cell carcinoma.


Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Autorenporträt
Dr. Mototsugu Oya Department of Urology, Keio University School of Medicine, Tokyo, Japan.